$17,81
▲ +$1,21
(+7,29%)
Vol. 5.5M
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$1.1B
ROE
-33,1%
D/E
0,00
Beta
1,19
52W
$1–$4
Consenso Wall Street
17 analisti · Apr 20265
Acquisto forte
9
Compra
2
Mantieni
1
Vendi
0
Vendita forte
82,4%
Rating Compra
Grafico dei Prezzi
Titoli simili
SRRK
Scholar Rock Holding Corp
$4.5B
COGT
Cogent Biosciences Inc
$5.4B
CGON
CG Oncology Inc
$3.3B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
PTCT
PTC Therapeutics Inc
P/E 8,1
$6.1B
CAI
Caris Life Sciences Inc
$7.6B
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10,6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70,7
$3.2B
IMVT
Immunovant Inc
$5.1B
Utili
Tasso di battuta: 50,0%
Prossimo report
Mag 11, 2026
Stima EPS: $-0,21
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,21 | — | — |
| Dic 2025 | $-0,11 | $-0,10 | +$0,01 |
| Set 2025 | $-0,11 | $-0,11 | $0,00 |
| Giu 2025 | $-0,11 | $-0,12 | $-0,01 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — | — |
| Utile netto | — | -$32.2M | -$31.0M | -$33.9M | -$30.6M | -$29.1M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -31.2% | -36.6% | -31.2% | -31.2% | -31.2% | -33.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 11.04 | 12.35 | 11.04 | 11.04 | 11.04 | 10.45 |
Rapporti chiave
ROA (TTM)
-27,8%
P/B
1,7
EPS (TTM)
$-0,45
CF/Share
$-1,57
52W High
$3,80
52W Low
$1,01
$1,01
Intervallo 52 settimane
$3,80
Salute finanziaria
Flusso di cassa libero
-$21.7M
Debito netto
-$26.7M
Liquidità
$73.8M
Debito totale
$47.1M
Aggiornato al Dic 31, 2025
Як ERAS виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка ERAS vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
—
▼
0%
sotto
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
1,7
▼
32%
sotto
peer
(2,5)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ERAS vs аналоги Biotechnology
ROE
-33,1%
▲
51%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Sotto media
Net margin
—
▼
0%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Top livello
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-27,8%
▲
41%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя ERAS vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
10,5
▲
135%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
1,2
▲
23%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ERAS
ERAS
Mediana peer
Industria
ERAS прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ERAS vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
MORRIS SHANNON R. M.D., PH.D.
Officer · Mar 04
20000 shs
MORRIS SHANNON R. M.D., PH.D.
Officer · Mar 04
20000 shs
GARNER EBUN S
General Counsel · Gen 07
120000 shs
GARNER EBUN S
General Counsel · Gen 07
120000 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 27,93%Frazier Life Sciences Manag…
7,31%
$340.3M
VR Adviser, LLC
5,75%
$267.3M
T. Rowe Price Investment Ma…
5,18%
$241.2M
Blackrock Inc.
5,02%
$233.5M
Suvretta Capital Management…
4,67%
$217.1M
Aggiornato al Dic 31, 2025